Jasper Therapeutics (JSPR) Other Operating Expenses (2020 - 2025)

Jasper Therapeutics has reported Other Operating Expenses for 5 years, with the latest figure at -$15.8 million in Q2 2025.

• On a quarterly basis, Other Operating Expenses fell 154.05% year-over-year to -$15.8 million in Q2 2025; TTM through Dec 2025 was -$25.5 million, a 107.27% decrease from a year earlier, with the FY2024 full-year figure at -$34.3 million, up 6.82% from the prior year.
• Other Operating Expenses was -$15.8 million for Q2 2025 at Jasper Therapeutics, down from -$9.8 million in the prior quarter.
• The five-year high for Other Operating Expenses was $8.4 million in Q4 2022, with the low at -$15.8 million in Q2 2025.
• Average Other Operating Expenses over 4 years is -$2.6 million, with a median of -$477500.0 recorded in 2022.
• The largest YoY upside for Other Operating Expenses was 8625.25% in 2022 against a maximum downside of 493.75% in 2022.
• Over 4 years, Other Operating Expenses stood at -$99000.0 in 2021, then surged by 8625.25% to $8.4 million in 2022, then sank by 173.54% to -$6.2 million in 2024, then sank by 154.05% to -$15.8 million in 2025.
• The last three Other Operating Expenses figures came in at -$15.8 million (Q2 2025), -$9.8 million (Q1 2025), and -$6.2 million (Q2 2024), per Business Quant data.